Therapeutic Asset Ratings

394 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
RITUXIMAB BIOSIMILAR (CELLTRION) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Merck Sharp & Dohme LLC	P3	CCC (52)
Sacituzumab Tirumotecan Breast Neoplasm	Merck Sharp & Dohme LLC	P3	CCC (52)
Sacituzumab Tirumotecan Fallopian Tube Cancer	Merck Sharp & Dohme LLC	P3	CCC (52)
her3-dxd Esophageal Cancer	Merck Sharp & Dohme LLC	P2	CCC (52)
Ifinatamab Deruxtecan Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (52)
mk-2214 Alzheimer Disease	Merck Sharp & Dohme LLC	P2	CCC (52)
Nemtabrutinib Follicular Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
Sacituzumab Tirumotecan Lung Cancer	Merck Sharp & Dohme LLC	P2	CCC (52)
Zilovertamab Vedotin Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
Zilovertamab Vedotin Follicular Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
Zilovertamab Vedotin Mantle Cell Lymphoma	Merck Sharp & Dohme LLC	P2	CCC (52)
MOXIFLOXACIN Schizophrenia	Merck Sharp & Dohme LLC	P1	CCC (52)
Avtozma B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
Favezelimab Esophageal Squamous Cell Carcinoma	Merck Sharp & Dohme LLC	P1/2	CCC (52)
mk-1045 B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
Siltuximab B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
Tyenne B-Cell Acute Lymphoblastic Leukemia	Merck Sharp & Dohme LLC	P2/3	CCC (52)
Belzutifan Breast Cancer	Merck Sharp & Dohme LLC	P2	CCC (51)
Favezelimab Endometrial Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (51)
mk-1167 Alzheimer Disease	Merck Sharp & Dohme LLC	P2	CCC (51)
Nemtabrutinib Hematopoietic And Lymphoid System Neoplasm	Merck Sharp & Dohme LLC	P2	CCC (51)
Pembrolizumab/Vibostolimab Coformulation Hepatocellular Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (51)
CIS-DIAMMINEDICHLOROPLATINUM II Advanced or Metastatic Solid Tumors	Merck Sharp & Dohme LLC	P1/2	CCC (51)
Ifinatamab Deruxtecan Prostate Cancer	Merck Sharp & Dohme LLC	P3	CCC (50)
Intismeran Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (50)

Showing 251 to 275 of 394 assets

PreviousPage 11 of 16Next